Evidence map›Paper›PMID 29100708›Full record

ArticleVaccine2017

Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.

Ana Cristina C Frota, Bianca Ferreira, Lee H Harrison, Gisele S Pereira, Wania Pereira-Manfro, Elizabeth S Machado, Ricardo Hugo de Oliveira, Thalita F Abreu, Lucimar G Milagres, Cristina B Hofer

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04875819 (Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04875819 phase4recruitingnot on this mapstarted 2021, after this paper: background citation

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV: A Single Center, Non-blinded, Randomized Clinical Trial

TypeinterventionalSponsorThomas BenfieldRan2021 to 2026Enrolled55ConditionsHiv, Meningococcal Infections, Pneumococcal InfectionsArmsNeisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020
    Guideline
  2. Innate-immune cell distribution in pediatric HIV patients and uninfected controls.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ana Cristina C FrotaPreventive Medicine Department, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: anacfrota@gmail.com.
Bianca FerreiraPreventive Medicine Department, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Lee H HarrisonUniversity of Pittsburgh, Pittsburgh, EUA, United States.
Gisele S PereiraState University of Rio de Janeiro, Department of Microbiology, Immunology and Parasitology, Rio de Janeiro, Brazil.
Wania Pereira-ManfroState University of Rio de Janeiro, Department of Microbiology, Immunology and Parasitology, Rio de Janeiro, Brazil.
Elizabeth S MachadoPreventive Medicine Department, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Ricardo Hugo de OliveiraInstituto de Puericultura e Pediatria Martagão Gesteira, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Thalita F AbreuInstituto de Puericultura e Pediatria Martagão Gesteira, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Lucimar G MilagresState University of Rio de Janeiro, Department of Microbiology, Immunology and Parasitology, Rio de Janeiro, Brazil.
Cristina B HoferPreventive Medicine Department, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Universidade Federal do Rio de Janeiro · BRUniversidade do Estado do Rio de Janeiro · BRUniversity of Pittsburgh · US

Funding

Real-Time PCR for Diagnosis of Culture-Negative Bacterial Meningitis in S?o PauloD43TW006592 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARRISON, LEE H · 2004 to 2013
$1.7M
Immunogenicity of meningococcal C conjugate vaccine in HIV infected childrenR01TW008397 · FIC · FEDERAL UNIVERSITY OF RIO DE JANEIRO · PI HOFER, CRISTINA BARROSO · 2009 to 2013
$250k
FIC NIH HHS D43 TW006592FIC NIH HHS R01 TW008397
6 · The paper itself

Abstract

We aimed to evaluate immunogenicity and adverse events (AEs) after a booster dose of Meningococcal C conjugated (MCC) vaccine in HIV-infected children and adolescents, who had a previous low seroconversion rate after priming with MCC, at a reference HIV-care center in Rio de Janeiro.

methods2-18 years old HIV-infected subjects with CD4+ T-lymphocyte cell (CD4) ≥15%, without active infection or antibiotic use, were enrolled to receive 2 doses of conjugated meningococcal C oligosaccharide-CRM197 12-18 months apart. All patients were evaluated before and 1-2 months after immunization for seroprotection [defined as human serum bactericidal activity (hSBA) titer ≥1:4]. AEs were assessed at 20 min, 3 and 7 days after each dose. Factors independently associated with seroprotection were studied.

results156 subjects were enrolled and 137 received a booster MCC dose. 55% were female, and median age was 12 years. Eight-nine percent were receiving combined antiretroviral therapy (cART) at the booster visit (median duration of 7.7 years), 59.9% had undetectable viral load (VL) at baseline, and 56.2% at the booster visit. Seroprotection was achieved in 78.8% (108/137) subjects, with a significantly higher GMT than after the priming dose (p < 0.01). Mild AEs were experienced after a second MCC dose (38%). In logistic regression, undetectable viral load at entry [odds ratio (OR) = 7.1, 95% confidence interval (95%CI): 2.14-23.37], and probably higher CD4 percent at the booster immunization visit (OR): 1.1, 95%CI: 1.01-1.17 were associated with seroprotection after a booster dose of MCC.

conclusionA booster dose of MCC was safe and induced high seroprotection rate even 12-18 months after priming. MCC should be administered after maximum virologic suppression has been achieved. These results support the recommendation of 2-dose of MCC for primary immunization in HIV-infected children and adolescents with restored immune function.

Indexed as

Blood Bactericidal ActivityAdolescentBrazilChildChild, PreschoolDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansImmunization, SecondaryMaleMeningococcal InfectionsMeningococcal VaccinesSurveys and QuestionnairesTreatment OutcomeMenC-CRM vaccineMeningococcal VaccinesBrazilChildrenHIVMeningococcal vaccine/adverse effectsMeningococcal vaccine/immunology

Identifiers

PMID29100708
PMCPMC12477987
OpenAlexW2765966919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.